<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=23487"><dc:title>Different glycosylation profiles of cystatin F alter the cytotoxic potential of natural killer cells</dc:title><dc:creator>Senjor,	Emanuela	(Avtor)
	</dc:creator><dc:creator>Pirro,	Martina	(Avtor)
	</dc:creator><dc:creator>Švajger,	Urban	(Avtor)
	</dc:creator><dc:creator>Prunk,	Mateja	(Avtor)
	</dc:creator><dc:creator>Sabotič,	Jerica	(Avtor)
	</dc:creator><dc:creator>Jewett,	Anahid	(Avtor)
	</dc:creator><dc:creator>Hensbergen,	Paul J.	(Avtor)
	</dc:creator><dc:creator>Perišić,	Milica	(Avtor)
	</dc:creator><dc:creator>Kos,	Janko	(Avtor)
	</dc:creator><dc:subject>cystatin F</dc:subject><dc:subject>immunosuppression</dc:subject><dc:subject>NK cells</dc:subject><dc:subject>N-Glycosylation</dc:subject><dc:description>Cystatin F, a cysteine peptidase inhibitor, is a potent modulator of NK cytotoxicity. By inhibiting granule-mediated cytotoxicity pathway, cystatin F induces formation of non-functional NK cell stage, called split-anergy. We show that N-glycosylation determines the localization and cellular function of cystatin F. Cystatin F mostly exhibited high-mannose glycosylation in U-937 cells, both high-mannose and complex glycosylation in NK-92 and primary NKs, and predominantly complex glycosylation in super-charged NKs. Manipulating N-glycosylation with kifunensine increased high-mannose glycosylation of cystatin F and lysosome localisation, which decreased cathepsin C activity and reduced NK cytotoxicity. Mannose-6-phosphate could significantly reduce the internalization of extracellular cystatin F. By comparing NK cells with different cytotoxic potentials, we found that high-mannose cystatin F was strongly associated with lysosomes and cathepsin C in NK-92 cell line. In contrast, in highly cytotoxic super-charged NKs, cystatin F with complex glycosylation was associated with the secretory pathway and less prone to inhibit cathepsin C. Modulating glycosylation to alter cystatin F localisation could increase the cytotoxicity of NK cells, thereby enhancing their therapeutic potential for treating cancer patients.</dc:description><dc:publisher>Springer Nature </dc:publisher><dc:date>2024</dc:date><dc:date>2025-09-04 13:33:53</dc:date><dc:type>Neznano</dc:type><dc:identifier>23487</dc:identifier><dc:source>Švica</dc:source><dc:language>sl</dc:language><dc:rights>© The Author(s) 2023</dc:rights></rdf:Description></rdf:RDF>
